Eye Health Product Manufacturing OTC in the US: Market Size, Businesses & Forecast 2026

The over-the-counter (OTC) eye health product manufacturing industry in the United States comprises the formulation and compounding of non-prescription ophthalmic solutions, ointments, and related vision-support products. Driven by a rising prevalence of age-related eye conditions and digital strain, the market shows resilient expansion. For instance, according to data compiled by the Consumer Healthcare Products Association, annual U.S. OTC eye care product sales reached 146 million units in 2024 (Consumer Healthcare Products Association). The industry's current trajectory is heavily influenced by intensifying regulatory requirements and automated manufacturing enhancements aimed at mitigat

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Eye Health Product Manufacturing OTC in the US industry cover?

This industry involves the specialized manufacturing of non-prescription ophthalmic remedies intended for self-care and direct consumer purchase. Primary product segments include lubricant eye drops, redness relievers, allergy drops, stye ointments, and contact lens solutions. These preparations are classified as over-the-counter drugs or medical devices and must meet stringent sterility specifications that differ from oral medications.

• •Products are primarily packaged as multi-dose bottles or single-use preservative-free vials.
• •Manufacturing practices must adhere strictly to current Good Manufacturing Practices (cGMPs) established by the federal government.
• •The scope excludes prescription-only ophthalmic pharmaceuticals and retail-level custom lens grinding.

Who operates in the industry and how is it structured?

The supply side is structured around advanced chemical processing facilities capable of maintaining cleanroom environments. Production is dominated by a mix of specialized ophthalmic multinational firms, broad-based consumer healthcare entities, and private-label contract manufacturing organizations. Distribution flows through established retail pharmacy chains, supermarkets, e-commerce networks, and specialized vision centers.

• •Facilities must register directly with the U.S. Food and Drug Administration (FDA) to supply the domestic market.
• •A large volume of private-label product is outsourced to generic or specialized contract drug manufacturers.
• •The industry relies heavily on complex supply chains for high-purity active ingredients and specialized sterile packaging components.

What drives demand in the industry?

Market demand is propelled by systemic demographic shifts and modern lifestyle habits that exacerbate vision discomfort. An aging domestic population naturally expands the patient base suffering from chronic ocular dryness and age-related maculopathy. Furthermore, the ubiquitous use of digital displays drastically elevates instances of screen-induced eye strain and dry eye disease across younger cohorts.

• •According to the National Eye Institute, dry eye disease affects approximately 16.4 million Americans, underscoring a vast target consumer base.
• •Decreased blinking rates associated with prolonged smartphone and computer usage accelerate tear film evaporation.
• •Growing consumer preference for preventative self-care drives initial utilization of OTC options over prescription alternatives.

Who are the notable companies in the industry?

Competition within the U.S. landscape is highly intense and characterized by major brand recognition alongside an expanding share of private-label alternatives. Major market players maintain extensive product portfolios that span multiple sub-categories, including allergy, dry eye, and redness relief. These operators differentiate through advanced product formulas, brand trust, and reliable retail distribution relationships.

• •Alcon Inc. maintains a prominent position, actively distributing its well-known Systane product line across the United States.
• •Bausch + Lomb Corporation represents a major operator, recording total dry eye portfolio revenues of 1.1 billion USD in 2025.
• •AbbVie Inc. engages in the OTC space with its broad consumer-facing Refresh brand catalog.
• •Kenvue Inc. and Rohto Pharmaceutical Co., Ltd. operate as significant participants via well-distributed eye-care and allergy portfolios.

What are the recent trends and outlook?

The outlook for the industry remains constructive, driven by a structural shift toward premium, preservative-free product segments. Manufacturers are increasingly modifying production lines to cater to the single-use vial format, which eliminates the need for chemical preservatives that can irritate sensitive ocular tissue. Additionally, companies are boosting capital expenditures to automate inspection and modernize compliance infrastructure.

• •Bausch + Lomb Corporation cited its OTC dry eye products and consumer franchises like Lumify as key performance drivers in late 2025.
• •E-commerce channels and virtual diagnoses are widening direct-to-consumer availability and brand discovery.
• •Advanced sterility assurance systems and environmental monitoring programs are capturing a higher share of operational budgets.

How is the industry regulated?

The industry operates under an exceptionally stringent regulatory framework due to the high risk associated with ophthalmic contamination. The U.S. Food and Drug Administration enforces absolute sterility standards, as eye drops bypass many of the body's natural defenses. Recent compliance actions have placed unprecedented pressure on domestic and international contract manufacturing facilities.

• •The FDA intensified oversight of OTC eye drop manufacturers following recurring contamination concerns and sterility recalls in recent years.
• •Regulatory enforcement includes warning letters and mandatory recalls for manufacturers utilizing unapproved active components or deficient quality testing.
• •Firms face frequent, unannounced site inspections checking for adherence to strict microbiological testing and validation protocols.

Government, statistical and trade sources used for this Claight analysis.

• Consumer Healthcare Products Association (CHPA) OTC Sales Statistics 2024 ·
• U.S. Food and Drug Administration (FDA) Ophthalmic Product Safety Alerts ·
• National Eye Institute (NEI) Dry Eye Statistics ·
• Bausch + Lomb Corporation Annual Earnings Report 2025